See more : Sumitomo Osaka Cement Co., Ltd. (SUCEF) Income Statement Analysis – Financial Results
Complete financial analysis of Anebulo Pharmaceuticals, Inc. (ANEB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anebulo Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SAS Florentaise (ALFLO.PA) Income Statement Analysis – Financial Results
- Korian (0OPS.L) Income Statement Analysis – Financial Results
- Golden Crest Education & Services Limited (GOLDENCREST.BO) Income Statement Analysis – Financial Results
- Huawen Media Group (000793.SZ) Income Statement Analysis – Financial Results
- Garrett Motion Inc. (GTX) Income Statement Analysis – Financial Results
Anebulo Pharmaceuticals, Inc. (ANEB)
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.55M | 5.60M | 2.96M | 2.27M | 150.00K |
| General & Administrative | 4.76M | 6.18M | 3.87M | 1.34M | 140.11K |
| Selling & Marketing | 4.80K | 0.00 | 0.00 | 0.00 | 23.21K |
| SG&A | 4.76M | 6.18M | 3.87M | 1.34M | 23.35K |
| Other Expenses | 0.00 | -41.15K | -1.78K | -1.34K | 0.00 |
| Operating Expenses | 8.31M | 11.78M | 6.83M | 3.61M | 173.35K |
| Cost & Expenses | 8.31M | 11.78M | 6.83M | 3.61M | 173.35K |
| Interest Income | 97.79K | 92.41K | 7.33K | 1.02K | 7.72 |
| Interest Expense | 0.00 | 0.00 | 7.33K | 11.77K | 1.29K |
| Depreciation & Amortization | 258.28K | 11.78M | 6.83M | 3.61M | 1.04M |
| EBITDA | -8.05M | -11.78M | 5.56K | -30.24M | -173.35K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.31M | -11.78M | -6.83M | -3.61M | -173.35K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 107.05K | 51.26K | 5.56K | -26.64M | -1.29K |
| Income Before Tax | -8.20M | -11.73M | -6.83M | -30.25M | -174.64K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -104.19K | -12.89K | 10.75K | -1.04K |
| Net Income | -8.20M | -11.73M | -6.81M | -30.26M | -174.64K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| EPS Diluted | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| Weighted Avg Shares Out | 25.82M | 25.07M | 23.34M | 23.34M | 23.72M |
| Weighted Avg Shares Out (Dil) | 25.82M | 25.07M | 23.34M | 23.34M | 23.72M |
Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001
Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication.
Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year?
Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.
Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year?
Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.
Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear
Anebulo pharmaceutical is a US small-cap ($80M market cap) biotech company that is developing a phase 2 asset for cannabis-related intoxication. ANEB-001 targets a cannabinoid intoxication; we do not believe the market potential for "acute intoxication" to be as lucrative...
Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants
Anebulo Pharmaceuticals Inc (NASDAQ: ANEB) has announced topline data from Part A of an ongoing Phase 2 trial of ANEB-001 to treat acute cannabinoid intoxication (ACI). Part A was a 60-subject trial designed to evaluate the effectiveness of a single dose of ANEB-001...
Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorders (the “Company” or “Anebulo”), today announced positive topline data from Part A of an...
Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), anticipates releasing topline data from Part A of its ongoing...
Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication
Anebulo Pharmaceuticals, Inc. ANEB announced financial results for the three months ended December 31, 2021 and recent updates. Q2 2022 Financial Highlights Operating expenses in the second quarter of fiscal 2022 were $1.1 million compared with $0.3 million in the...
8 of the Hottest Cannabis Stocks Right Now
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.
Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem
Photo by Elsa Olofsson on Unsplash Many people today remain unaware of the risks an overdose of marijuana carries. In fact, some people don't believe overdosing on cannabis to be possible.
Source: https://incomestatements.info
Category: Stock Reports